Q2 2026 Solara Active Pharma Sciences Ltd Earnings Call Transcript
Key Points
- Solara Active Pharma Sciences Ltd (BOM:541540) successfully cleared a US FDA audit at their Mangalore facility with only two minor procedural observations.
- The company maintains a strong gross margin profile of 51%, despite short-term disruptions.
- Solara Active Pharma Sciences Ltd (BOM:541540) has reduced its debt by INR153 crore during H1 FY26, reflecting a 20% reduction in opening debt.
- The company is focusing on sustainable, scalable, and reliable growth, with an emphasis on operational deliveries and business expansion.
- Solara Active Pharma Sciences Ltd (BOM:541540) has a strong presence in regulated markets, contributing 75% of overall sales.
- The company's financial performance was impacted by an unscheduled operational shutdown at the Mangalore facility, leading to delayed deliveries and reduced volumes.
- There was a marginal decline in revenue by 2% QoQ, with a significant impact on EBITDA, which saw a degrowth of close to 39% QoQ.
- Operating costs increased by INR9 crore QoQ, driven by annual cost increases and one-time upgradation costs.
- The company experienced a decline in gross margins due to a change in product mix and deferred delivery of higher-margin products.
- Solara Active Pharma Sciences Ltd (BOM:541540) faces liquidity challenges, with net current liabilities exceeding assets by over INR70 crore.
Ladies and gentlemen, good day and welcome to Solara Active Pharma Sciences Limited Q2 FY26 earnings conference call.
(Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Abhishek. Thank you and over to you, sir.
Thank you. Very good afternoon and thank you for joining us today for Solara earnings call for the second quarter and half year ended financial year 2026.
Today, we have with us Sandeep Rao, MD and CEO; and Sarat Kumar, CFO of the company to share the highlights of the business and financials for the quarter.
I hope you've gone through our results release; and the quarterly investor presentation that have been uploaded on our website, as well as stock exchange website.
The transcript for this call will be available in a week's time on the company's website.
Please note that today's discussion may be forward-looking in nature and must be viewed in relation to the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
